NKT5097 CDK2/CDK4 dual degrader

Phase 1Small molecule

NKT5097 CDK2/CDK4 dual degrader is one of 3 small molecule programs targeting HR+ Breast Cancer. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HR+ Breast CancerRecruiting

HR+ Breast CancerPhase 1

Recruiting

Competition

Competitive Landscape

2 competitors in HR+ Breast Cancer

#DrugCompanyPhaseTrials

Femara

Novartis

Phase 1

1 2

Faslodex

FFresenius Kabi Oncology Ltd.

Phase 1

1 3

NKT5097 CDK2/CDK4 dual degrader

NNiKang Therapeutics, Inc.

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 1Recruiting

HR+ Breast Cancer

NCT07029399

Clinical

Trials by Indication[1]

HR+ Breast Cancer1 trial

A Phase 1, First-in-Human, Open-Label Study to Evaluate the Safety, Tolerability, PK, and Preliminary Anti-tumor Activity of the Novel Oral Selective CDK2/CDK4 Dual Degrader NKT5097 in Adults With Advanced/Metastatic Solid Tumors

Recruiting·NNiKang Therapeutics, Inc.·Phase 1·NCT07029399·361 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for NKT5097 CDK2/CDK4 dual degrader. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — NKT5097 CDK2/CDK4 dual degrader compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for NKT5097 CDK2/CDK4 dual degrader. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — NiKang Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: NNiKang Therapeutics, Inc.

NKT5097 CDK2/CDK4 dual degrader

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

HR+ Breast Cancer1 trial

References

Drug Info

Quick Facts

Related News